D-0834-2020 Class II Terminated

Recalled by Zydus Pharmaceuticals USA Inc — Pennington, NJ

FDA drug recall D-0834-2020 was initiated by Zydus Pharmaceuticals USA Inc on Jan 31, 2020 and is designated Class II. Reason for recall: cGMP Deviations The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 2207 Vials.

Recall details

Product Type
Drugs
Report Date
Feb 19, 2020
Initiation Date
Jan 31, 2020
Termination Date
Oct 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2207 Vials

Product description

Ethacrynate Sodium for Injection, USP, 50mg/vial, Single Dose Vial, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-246-01.

Reason for recall

cGMP Deviations

Distribution pattern

Nationwide in the U.S.

Code information

Lot #s: M804062, Exp. 01/2020; M804063, M804064, Exp. 02/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0834-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0834-2020. Report a data issue: hello@regdatalab.com.